RELUMINATE

Serial Number 87486030
606

Registration Progress

Application Filed
Jun 13, 2017
Under Examination
May 22, 2018
Approved for Publication
Mar 27, 2018
Published for Opposition
Mar 27, 2018
Registered

Trademark Image

RELUMINATE

Basic Information

Serial Number
87486030
Filing Date
June 13, 2017
Published for Opposition
March 27, 2018
Abandonment Date
June 28, 2021
Drawing Code
4000

Status Summary

Current Status
Inactive
Status Code
606
Status Date
Jun 28, 2021
Classes
005

Rights Holder

Alkermes Pharma Ireland Limited

03
Address
1 BURLINGTON ROAD
CONNAUGHT HOUSE
DUBLIN
IE

Ownership History

Alkermes Pharma Ireland Limited

Original Applicant
03
DUBLIN IE

Alkermes Pharma Ireland Limited

Owner at Publication
03
DUBLIN IE

Legal Representation

Attorney
Norm J. Rich

USPTO Deadlines

All Deadlines Cleared

All 5 deadline(s) have been cleared by subsequent events. No active deadlines at this time.

Application History

37 events
Date Code Type Description Documents
Jun 28, 2021 ABN6 S ABANDONMENT - NO USE STATEMENT FILED Loading...
Jun 28, 2021 MAB6 E ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED Loading...
Nov 7, 2020 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED Loading...
Nov 6, 2020 AITU A CASE ASSIGNED TO INTENT TO USE PARALEGAL Loading...
Nov 6, 2020 EX5G S SOU EXTENSION 5 GRANTED Loading...
Oct 29, 2020 EEXT I SOU TEAS EXTENSION RECEIVED Loading...
Oct 29, 2020 EXT5 S SOU EXTENSION 5 FILED Loading...
Apr 22, 2020 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED Loading...
Apr 20, 2020 EEXT I SOU TEAS EXTENSION RECEIVED Loading...
Apr 20, 2020 EXT4 S SOU EXTENSION 4 FILED Loading...
Apr 20, 2020 EX4G S SOU EXTENSION 4 GRANTED Loading...
Nov 1, 2019 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED Loading...
Oct 30, 2019 EEXT I SOU TEAS EXTENSION RECEIVED Loading...
Oct 30, 2019 EXT3 S SOU EXTENSION 3 FILED Loading...
Oct 30, 2019 EX3G S SOU EXTENSION 3 GRANTED Loading...
May 22, 2019 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED Loading...
May 20, 2019 EEXT I SOU TEAS EXTENSION RECEIVED Loading...
May 20, 2019 EXT2 S SOU EXTENSION 2 FILED Loading...
May 20, 2019 EX2G S SOU EXTENSION 2 GRANTED Loading...
Sep 4, 2018 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED Loading...
Aug 31, 2018 EEXT I SOU TEAS EXTENSION RECEIVED Loading...
Aug 31, 2018 EXT1 S SOU EXTENSION 1 FILED Loading...
Aug 31, 2018 EX1G S SOU EXTENSION 1 GRANTED Loading...
May 22, 2018 NOAM E NOA E-MAILED - SOU REQUIRED FROM APPLICANT Loading...
Mar 27, 2018 PUBO A PUBLISHED FOR OPPOSITION Loading...
Mar 27, 2018 NPUB E OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED Loading...
Mar 7, 2018 NONP E NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED Loading...
Feb 20, 2018 CNSA P APPROVED FOR PUB - PRINCIPAL REGISTER Loading...
Feb 3, 2018 TEME I TEAS/EMAIL CORRESPONDENCE ENTERED Loading...
Feb 2, 2018 TROA I TEAS RESPONSE TO OFFICE ACTION RECEIVED Loading...
Feb 2, 2018 CRFA I CORRESPONDENCE RECEIVED IN LAW OFFICE Loading...
Aug 4, 2017 CNRT R NON-FINAL ACTION WRITTEN Loading...
Aug 4, 2017 GNRT F NON-FINAL ACTION E-MAILED Loading...
Aug 4, 2017 GNRN O NOTIFICATION OF NON-FINAL ACTION E-MAILED Loading...
Jul 21, 2017 DOCK D ASSIGNED TO EXAMINER Loading...
Jun 19, 2017 NWOS I NEW APPLICATION OFFICE SUPPLIED DATA ENTERED Loading...
Jun 16, 2017 NWAP I NEW APPLICATION ENTERED Loading...

Detailed Classifications

Class 005
Prescription pharmaceutical preparations for the treatment of diseases mediated by an opioid receptor, namely, major depressive disorder, chronic depression, severe unipolar recurrent major depressive episodes, dysthymic disorder, depressive neurosis and neurotic depression, melancholic depression, atypical depression, reactive depression, treatment resistant depression, seasonal affective disorder and pediatric depression, premenstrual syndrome, premenstrual dysphoric disorder, hot flashes, bipolar disorders or manic depression, bipolar I disorder, bipolar II disorder and cyclothymic disorder, anxiety, post-traumatic stress disorder, obsessive compulsive disorder and borderline personality disorder
First Use Anywhere: 0
First Use in Commerce: 0

Classification

International Classes
005